PLoS One by Gates, Irina et al.
RESEARCH ARTICLE
Development of a High-Content
Orthopoxvirus Infectivity and Neutralization
Assays
Irina Gates1*, Victoria Olson2, Scott Smith2, Nishi Patel2, Inger Damon2, Kevin Karem2
1 Atlanta Research and Education Foundation, Decatur, Georgia, United States of America, 2 Poxvirus and
Rabies Branch, Division of High-Consequence Pathogens and Pathology (DHCPP), National Center for
Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention, Atlanta,
Georgia, Unites States of America
* irina.gates@gmail.com
Abstract
Currently, a number of assays measure Orthopoxvirus neutralization with serum from
individuals, vaccinated against smallpox. In addition to the traditional plaque reduction neu-
tralization test (PRNT), newer higher throughput assays are based on neutralization of
recombinant vaccinia virus, expressing reporter genes such as β-galactosidase or green
fluorescent protein. These methods could not be used to evaluate neutralization of variola
virus, since genetic manipulations of this virus are prohibited by international agreements.
Currently, PRNT is the assay of choice to measure neutralization of variola virus. However,
PRNT assays are time consuming, labor intensive, and require considerable volume of
serum sample for testing. Here, we describe the development of a high-throughput, cell-
based imaging assay that can be used to measure neutralization, and characterize replica-
tion kinetics of various Orthopoxviruses, including variola, vaccinia, monkeypox, and
cowpox.
Introduction
Variola virus is the etiological agent of smallpox, arguably the most lethal infectious disease of
man in history. International efforts, including a world-wide vaccination campaign, resulted in
eradication of smallpox in 1980 [1]. Subsequent cessation of routine vaccination caused the
global community to become increasingly vulnerable to Orthopoxvirus infections as a result of
waning immunity [1]. In recent years, research and development for therapies and safer vac-
cines have been driven by concerns over use of variola virus as an agent of bioterrorism, or
emergence of other Orthopoxvirus infections as public health threats [2, 3]. Stockpiles of vac-
cine are currently held in many countries, including the United States, in order to vaccinate the
populations in the event of a smallpox reintroduction. However, existing vaccines remain
unsafe for people in certain risk categories, including infants, pregnant and breastfeeding
women, people with immunodeficiency or those who are likely to experience adverse side
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effects [4]. Research to develop next generation smallpox vaccines requires some measure of
immune efficacy in the absence of an animal model susceptible to variola virus infection. As
such, these new vaccines will require efficacy testing to show non-inferiority to first generation
smallpox vaccines. Studies for efficacy may include animal models using other Orthopoxvirus
infection, immune assays to measure induced immunity, and functional assays such as in vitro
viral neutralization tests. In vitro assays traditionally used to monitor humoral immunity
include a traditional plaque reduction neutralization test (PRNT) for poxviruses. Traditional
PRNT assays have been a benchmark for poxvirus neutralization for decades. However, they
are low-throughput, labor-intensive, require a large amount of serum and significant amounts
of time to perform ranging between 48–72 hours. Contemporary high-throughput assays have
been developed that increase dynamic range, shorten protocol time, decrease serum volume
required for assay, and improve reproducibility [5, 6, 7, 8]. However, these newer assays rely on
recombinant vaccinia viruses in order to measure viral infection via fluorescent or luminescent
methods. Recombination of variola virus is prohibited internationally under the authority of
the World Health Organization, forbidding manipulation of variola virus for use in existing
high throughput assays [9]. We therefore sought to develop a high-throughput neutralization
assay for use with variola virus without the requirement of genetic manipulation. Exploiting
the known immunological cross-reactivity between members of Orthopoxviruses, and the
availability of commercial polyclonal antibodies against vaccinia virus, we designed infectivity
and neutralization assays that do not require use of recombinant viruses and are compatible
with different species of the Orthopoxvirus genus. We initially developed high-throughput,
high-content infectivity and neutralization assays using vaccinia virus and applied the method
to measure infectivity and neutralization of variola, cowpox, and monkeypox viruses.
Materials and Methods
Cells, viral stocks, Vaccinia Immune Globulin (VIG) and staining
procedure
Vero E6 cells (ATCC CRL1586) were maintained in growth medium containing DMEM with
Glutamax (Life Technologies), supplemented with 10% of heat-inactivated FBS (HyClone),
100 units/mL of Penicillin and 100ug/mL of Streptomycin (Life Technologies) and were sub-
cultured twice a week using Accumax (Innovative Cell Technologies) as detachment reagent.
Cell infections were carried out in medium that contained 2% FBS, 100 units/mL of Penicillin
and 100ug/mL of Streptomycin. The following Orthopoxviruses were used in assay develop-
ment: vaccinia Wyeth, vaccinia Western Reserve, variola Solaimen, monkeypox USA-2003-44,
and cowpox Brighton. All work with variola virus was additionally reviewed and approved by
the World Health Organization (WHO) Technical Advisory Committee on variola virus
research. Viral stocks were generated at different times according to standard laboratory proto-
cols in which Orthopoxviruses were grown in BSC-40 cells, harvested and purified by sedimen-
tation through sucrose cushion. Viral potencies were determined by plaque assay on BSC-40
cells monolayer. VIG (lot # 1730206) was received from Cangene Corporation (Winnipeg,
Canada), and used for neutralization assay development experiments.
For imaging assays to detect virus presence, infected cells were fixed with 4% formaldehyde
(Pierce, Rockford, IL. USA), followed by permeabilization with 0.5% Triton X-100 (Sigma,
St. Louis, MO, USA). Viral presence was detected with rabbit anti-vaccinia polyclonal antibody
(Virostat, Portlamd, ME, USA), and counterstained with goat anti-rabbit antibody conjugated
to Alexa Fluor 488. DAPI stain was used for identification of cellular nuclei, and HCS Cell
Mask Deep Red Cell Stain for staining of cellular cytoplasm (Life Technologies). Images were
acquired on the ArrayScan high content instrument (Thermo Scientific), using 5X objective,
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excitation wavelengths at 350, 488 and 633 nm, and emission data collection at 470, 519, and
665nm, correspondingly. With 5X magnification, the three fluorescent signals were collected
from 9 fields per well, which is the maximum number of fields possible to collect at selected
magnification. Image analysis was done using Columbus Scope software (Perkin Elmer).
High Content Infectivity Assay (HC-IA)
Vero E6 cells were plated in growth medium in black 96-well, clear bottom plates (Perkin
Elmer, Whaltham, MA, USA) at 1.7x104 cells per well and were allowed to attach overnight at
37°C, 5% CO2. On the day of infection viral stocks were sonicated three times for one minute
with 20-second incubations on ice between sonications and pre-diluted 100-fold, using 2% FBS
infection medium. Further viral dilutions were prepared in dilution plates and then transferred
onto test plates. At the infection step, growth medium was removed from test plates and
replaced with 50uL/well of virus. Infected cells were incubated at 37°C, 5% CO2. For experi-
ments with variola virus, the incubation temperature was 35.5°C. In order to find optimal assay
conditions we evaluated growth dynamics for each virus, and prepared multiple plates to test
different incubation times. Infectivity assays were established using vaccinia Wyeth virus,
which was prepared in a series of nine two-fold dilutions, starting from an intended MOI = 1
(1.7x104 pfu/well), followed by MOIs of 0.5, 0.25, 0.125, etc. (Fig 1). Vero E6 cells were infected
with 50uL per well of viral dilutions, in duplicates and incubated for 5, 7, 17 and 24 hours at
37°C. Each plate had 4–6 wells with infection medium only, that were used as uninfected con-
trol for data analysis. At the end of each incubation period, cells were fixed with formaldehyde
and stained with anti-vaccinia virus polyclonal antibody.
Plaque Assay
Plaque assay was used to determine viral titers for the stocks used during assay development
and method comparison experiments. Vero E6 cells were plated in 6-well dishes (Corning,
Tewksbury, Mass) at 1.4x106 cells per well and incubated overnight at 37°C, 5% CO2. Virus
samples were sonicated three times at 160 Watts for one minute with 20-second incubations
on ice between sonications. Ten-fold dilutions were prepared for each viral stock from 10−3 to
10−8. Growth medium was replaced with 1mL per well of virus suspension at each different
dilution, in duplicates. Infected plates were incubated at 37°C, 5% CO2 for one hour, and then,
viral inoculum was replaced with 2% FBS infection medium. Plates with infected cells were
incubated at 37°C, 5% CO2 for 48 hours. Cells infected with variola virus were incubated at
35.5°C, 5% CO2 for 96 hours. Monolayers were subsequently fixed and stained with crystal vio-
let containing 10% formalin. Plaques were counted and concentrations for each stock were cal-
culated using the following formula:
Mean number of plaques
Inoculum per well ðmLÞ  Dilution factor for the well
Concordance between HC-IA and plaque assay
For comparison and correlation between HC-IA and traditional plaque assays, we used 13 vac-
cinia virus stocks. For HC-IA, a viral stock with known titer from previously performed plaque
assay was used as “reference” starting at a multiplicity of infection (MOI) ranging from 0.3–
0.6. Viral stocks with unknown titers were treated as “samples” and were initially run at a
1:1500 starting dilution. When required, viral stocks with low titers were re-tested at a 1:200 or
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1:1000 starting dilution, followed by a series of two-fold dilutions. For the comparison with pla-
que assay, all viral stocks were tested following the procedure described above.
Development of Staining Procedure with 5%MicroChem-Plus
inactivation treatment
Variola virus infectivity and neutralization experiments were performed in a BSL- 4 laboratory
and experimental plates were required to be disinfected before transporting to BSL- 2 labora-
tory for data acquisition. In compliance with an Environment, Safety, and Health Compliance
Office (ESCHO) approved protocol, 5% MicroChem-Plus (National Chemical Laboratories
Inc, Philadelphia, PA, USA) was used to disinfect all material from the BSL- 4 before being
removed from the laboratory. We evaluated the effect of MicroChem-Plus treatment on immu-
nostaining by comparing fluorescent intensity between different staining conditions. Staining
conditions with MicroChem-Plus treatment were optimized in the BSL- 2 laboratory using
vaccinia virus. Following the developed infectivity assay protocol (HC-IA), Vero E6 cells were
infected at MOI 0.25 and incubated for 17 hours. After fixation with 4% formaldehyde, wells in
96-wellplate were divided into four groups depending on the order cells were treated with 5%
MicroChem-Plus, and included the following: “NoMicroChem-Plus” which was used as a
Fig 1. Infection dynamics. Infection dynamics were tested in Vero E6 cells for four different types of Orthopoxviruses. Cells were infected with viral titrations
starting fromMOI 1 (1.7x104 pfu/well), X-axis, followed by a series of two-fold dilutions down to a lowest multiplicity infection of 3.9x10-4 for vaccinia virus, and
9.76x10-4 for variola, cowpox and monkeypox viruses. The Y-axis corresponds to percent of infected cells. Incubation times ranged from 5–28 hours post
infection (hpi). NC = Negative control.
doi:10.1371/journal.pone.0138836.g001
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control condition, “After fixation” (MicroChem-Plus added post fixation step), “After permea-
bilization” (MicroChem-Plus added after permeabilization step), and “After secondary anti-
body” (MicroChem-Plus added after last step of staining protocol). MicroChem-Plus
treatment lasted 5 minutes, and was followed with 5 washes with PBS.
High Content Orthopoxvirus Neutralization Assay (HC-OVNA)
Vero E6 cells were plated in growth medium in black 96-well, clear bottom plates at 1.7x104
cells per well and were used the following day. During assay development VIG was used to
assess neutralization of tested Orthopoxviruses. VIG and Orthopoxviruses were prepared at 2X
concentration and then mixed together in equal volumes, followed by a 30 minute pre-incuba-
tion at 37°C. At the end of pre-incubation, growth medium from the assay plate was replaced
with pre-incubated mixture of virus and VIG and incubated for 17 hours at 37°C, 5% CO2.
VIG was prepared at three-fold serial dilutions, starting at 1:25 dilution (2X) and mixed with
the virus at MOI 0.5 (2X). Every test plate had four medium only and virus only wells that were
used as non-infected and infected controls, respectively. After a 17 hours incubation, cells were
fixed, permeabilized, and stained with anti-vaccinia antibody for virus detection, as described
in HC-IA, with the addition of the 5%MicroChem-Plus treatment step for the variola virus
based assay. According to the protocol, microtiter plates containing formaldehyde-fixed variola
virus were submerged into 5%MicroChem-Plus solution for 5 minutes and then were trans-
ferred to BSL-2 laboratory. MicroChem-Plus solution was removed and plates were washed
five times with PBS. Results were acquired on ArrayScan and analyzed using Columbus soft-
ware and reported as percent infected cells per well. The dilution at which 50% of cells are
neutralized was calculated in GraphPad Prizm, using a sigmoidal dose-response nonlinear
regression algorithm.
Data Acquisition and Analysis
Image analysis was performed using Columbus Scope software, where all cells were identified
first by nuclear (DAPI) and cytoplasmic staining (HCS Cell Mask Deep Red Stain). Cells
infected with virus were identified with rabbit anti-vaccinia virus antibody, following by fluo-
rescently labeled anti-rabbit antibody. The numbers of infected and non-infected cells were
scored and the percent of infected cells was calculated by dividing the number of “infected”
cells by the number of “total cells” identified in the well and multiplying the resulted ratio by
100%.
During virus titration experiments, we observed that the percent of infected cells directly
correlated with viral concentration. The highest percent of infected cells was detected in the
wells that had high concentrations of virus and detection of infected cells gradually decreased
with each additional virus dilution step. For the viral stocks with known starting titers (pfu/
mL) we calculated an expected viral concentration for each dilution point in a dilution series
and then correlated it to corresponding percent of infected cells. We employed GraphPad
Prizm software, version 5 (La Jolla, CA, USA) to graph the results of virus infection, where esti-
mated virus titers (pfu/mL) in a log-transformed dilution series were positioned on the X-axis
and percent of infected cells were on the Y-axis. Data was analyzed using non-linear regression
sigmoidal dose-response variable slope algorithm. Since viral stocks that were used for infec-
tion dynamics experiments had known starting titers, calculated infectious concentrations 50%
(IC50) were reported in pfu/mL and MOI.
In the high-content infectivity assay, we used Parallel Line Analysis Software PLA 2.0
(Stegmann Systems, Rodgau, Germany) to calculate relative titers (pfu/mL) for samples with
unknown potency from reference stocks with known pfu/mL concentrations that were
Orthopoxvirus Infectivity and Neutralization Assays
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previously determined by plaque assay. Log-transformed dilution series for reference stocks
and samples were plotted on the X-axis and corresponding percent of infected cells on the Y-
axis. For analysis, we used four-parameter logistic curve and calculated dilution at IC50 for
samples and reference standard. The relative potency is the exponentiated distance between
IC50 value of the reference stock and IC50 value of the sample. Since reference stock had a
known starting concentration and the reference standard is similar to the sample, the relative
potency was used as a factor to estimate the potency of the sample. For the high-content
Orthopoxvirus neutralization assay, the half maximum effective concentration (EC50) values
were calculated using GraphPad Prizm software. Percent of infected cells (y-axis) were plotted
against serum dilutions (x-axis) generating a sigmoidal curve. Serum dilutions that resulted in
50% neutralization of viral infection were calculated using non-linear regression sigmoidal
dose-response (variable slope) algorithm.
To evaluate assay reproducibility, we applied Z-factor statistical method, which is com-
monly used to estimate reproducibility and robustness of screening assays. This parameter
assesses, in part, assay quality by calculating separation between positive and negative signals.
Calculated Z-factor values between 1 and 0.5 refer to an excellent assay, while values between
0.5 and 0 indicate a marginal assay. Z-factor was calculated using the following formula [10]:
Z ¼ 1 3  ðSD Infected þ SD NeutralizedÞðMean Infected  Mean NeutralizedÞ
In concordance evaluation between HC-OVNA and HCS-GFP assays, results from
HCS-GFP neutralization assay were analyzed in GraphPad Prizm using a variable slope sig-
moidal equation, as previously described [6]. Calculated inhibitory concentration 50 (ID50)
that neutralizes 50% of vaccinia virus Western Reserve GFP expressing virus in HCS-GFP
assay was compared to EC50 values from HC-OVNA. Results from both assays were compared
for each sample and analyzed in GraphPad Prizm using correlation algorithm with 95% confi-
dence interval in two-tailed test.
To evaluate the agreement between plaque assay and HC-IA we used GraphPad Prizm cor-
relation algorithm with 95% confidence interval in two-tailed test and compared titers from
plaque assay to relative potency values from HC-IA.
Evaluation of serum neutralizing activity from monkeypox virus
challenged prairie dogs
Serum samples from prairie dogs (PDs) infected with monkeypox virus study were kindly pro-
vided by Christina Hutson [11]. Collected serum samples were from two prairie dogs intrana-
sally challenged with West African monkeypox virus (strain MPXV-USA-2003-044, collected
during the 2003 U.S. outbreak) at 5 x 103 pfu and included sera collected on days 3, 6, 13, 20,
24 post-challenge and on the day 31 when they were euthanized. We evaluated virus neutrali-
zation using vaccinia virus Wyeth strain, where prairie dog serum samples were tested at titra-
tion ranging from 1:40 to 1:40960, in a series of four-fold dilutions. As per the developed
HC-OVNA protocol, equal volumes of vaccinia virus were mixed with titration of PD serum
and pre-incubated for 30 minutes at 37°C, followed by 17 hours infection of Vero cells.
Correlation between HC-OVNA and HCS-GFP
The HCS-GFP Neutralization Assay has been previously described [6] and is based on recom-
binant vaccinia virus Western Reserve virus expressing green-fluorescent protein (WR-GFP).
Agreement between HC-OVNA and HCS-GFP assays was assessed with 49 human serum sam-
ples from the study “Evaluation of the Serologic Diagnostics for DryVax Smallpox Vaccine”,
Orthopoxvirus Infectivity and Neutralization Assays
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collected according to CDC Institutional Review Board protocol 3349. Available serum samples
were divided into four categories: Category “A” consisted of serum collected from participants
that were vaccinated with smallpox vaccine for the first time at adulthood; Category “B”
includes serum from individuals that were vaccinated at adulthood and were boosted 3 years
after first vaccination; Category “C” included individuals previously vaccinated at childhood
(30 + years) and boosted once in adulthood; Category “D” included serum from individuals
that were vaccinated in childhood and boosted multiple times in adulthood (Table 1). For each
category, the following time points were selected: day 0, day 7, day 21 and 6 months post vacci-
nation with DryVax vaccine. Each serum sample was tested on three separate days by each
assay. Samples were tested in four-fold serial dilutions ranging from 1:40 to 1:40960 and were
prepared according to each assay procedure. Results for each assays were acquired on ArrayS-
can. Collected images for HC-OVNA were analyzed using Columbus Scope algorithm and
then plotted using GraphPad Prism 5.0 software. Images from HCS-GFP assay were analyzed
using Target activation, version 3 algorithm from ArrayScan, followed by analysis using
GraphPad Prizm [6]. For correlation analysis EC50 values from HC-OVNA were plotted
against ID50 values from HCS-GFP assay and analyzed in GraphPad Prizm.
Results
Infectivity assays were established using vaccinia Wyeth virus. The fluorescent signal associated
with vaccinia virus infection at MOI 1 was reproducibly detectable at 5 and 7 hours post infec-
tion (hpi) and corresponded to 15% and 40% of cells infected, respectively (Fig 1). Infections at
MOIs of 0.5, 0.25 and lower showed significantly less fluorescent signal at early time points. An
MOI of 0.5 corresponded to 3% and 18% of infected cells for 5hpi and 7hpi, respectively, result-
ing in a low dynamic range. However, infections at 17 and 24 hours showed that percent of
infected cells increased up to 95% at MOI 1, 0.5, and 0.25. Based on these results we selected 17
hours incubation time for vaccinia virus infection experiments, which allowed us to have a
rapid high-throughput assay.
Time course experiments were performed with similar dilution ranges for variola, cowpox
and monkeypox viruses. Infection dynamics for these viruses are slower than we observed with
vaccinia virus and required longer incubation times, ranging between 24–28 hours in order to
reach a minimum of 90% of infected cells per well (Table 2). For vaccinia virus the infectious
concentration 50 (IC50) values at 17 hours post infection were 1.65x10
4 pfu/mL, that corre-
sponded to MOI 0.055, while for cowpox virus the IC50 value was 1.57x10
5pfu/ml (MOI 0.53).
By 24hpi all tested Orthopoxviruses had a percent of infected cells above 90% for the first dilu-
tion point (an intended MOI 1) with 3 to 5 fold difference in IC50 values. Still, vaccinia virus
continues to have the fastest infection dynamics (IC50−1.01x10
4 pfu/mL, or MOI 0.035), while
Table 1. Four categories of human serum samples selected for the study.
Vaccination status Childhood Adult 1 Adult 2 Adult 3+
Adult only (“A”); n = 3 - X* - -
Adult primary and boosted 3 years (“B”); n = 3 - X X* -
Childhood primary and boosted once at adulthood (“C”); n = 5 X X* - -
Childhood primary and multiple boosts at adulthood (“D”); n = 7 ª X X X* X*
ª Results include samples from adult boost vaccinations collected at different times for the same individuals.
X*—Indicates serum samples collected at selected vaccination time.
X—Indicates previous vaccination times.
doi:10.1371/journal.pone.0138836.t001
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monkeypox virus infection was the slowest (IC50−4.75 x10
4 pfu/mL, MOI 0.158). Cowpox and
variola viruses had somewhat similar infection dynamics with IC50−2.55 x 10
4 pfu/mL (MOI
0.095) and 3.25 x104 pfu/mL (MOI 0.108) respectively. As a result we selected 24 hours incuba-
tion time for infections with variola, monkeypox and cowpox viruses.
Fig 2 represents variola virus infection at different MOI concentrations, detected at 24 hours
post infection. The number of infected cells is the highest at MOI 1 and gradually decreasing
with virus titrations, allowing to identify an individual foci.
Development of Staining Procedure with 5%MicroChem-Plus treatment
To evaluate the effect of MicroChem-Plus disinfecting reagent on signal intensity from the
virus stained with anti-vaccinia polyclonal detection antibody, 5% solution of MicroChem-
Plus was applied at different steps of staining protocol. MicroChem-Plus treatment had a mini-
mum effect on vaccinia virus signal intensity when incorporated at the end of the staining pro-
tocol. Signal from the wells that received MicroChem-Plus was comparable to the signal of
control wells (Fig 3). However, signal intensity decreased when MicroChem-Plus was intro-
duced after fixation or permeabilization step. Due to the drop in signal intensity when Micro-
Chem-Plus treatment occurred prior to staining, all immunostaining steps for experiments
with variola virus were conducted within the BSL- 4 and MicroChem-Plus treatment occurred
at the end of the staining procedure.
Correlation study between HC-IA and Plaque Assay
We evaluated the correlation between the HC-IA and standard plaque assay using vaccinia
Western Reserve and vaccinia Wyeth virus strains (Fig 4). Thirteen vaccinia virus stocks were
tested in duplicate with both assays. The majority of viral stocks had titers between 108−109
pfu/mL and were tested in high content infectivity assays starting at a 1:1000 dilution, followed
by two-fold serial dilutions. With these starting dilutions, a few low titer viral stocks infected
less than 50% of cells per well, instead of the targeted 90–95%, after 17 hours of incubation.
These stocks were re-tested with starting dilution at 1:200, followed by eleven 2-fold dilutions,
which resulted in 90–95% of cells per well detected as infected at the lowest dilution tested. For
future experiments we decided to follow the rule that if stock is expected to have potency at
108−109 pfu/mL, then the starting dilution should be at 1:1000, but for any stocks with lower or
unknown potency, a starting dilution at 1:200 dilution, followed by eleven 2-fold dilutions was
used.
The results from the HC-IA method were reported as percent of infected cells per well. In
order to calculate the relative potency (pfu/mL) of viral stocks with the HC-IA, PLA software
was utilized. Selected reference stock sample had a known viral titer (pfu/mL) previously deter-
mined by plaque assay. The HC-IA method results were plotted and analyzed with four-
parameter logistic fit algorithm. The IC50 dilution values in the HC-IA for the reference and
Table 2. IC50 infectivity values for tested Orthopoxviruses.
HPI Vaccinia Cowpox Monkeypox Variola
pfu/mL MOI pfu/mL MOI pfu/mL MOI pfu/mL MOI
17 1.65x104 0.055 1.57x105 0.53 – – – –
20 – – – – – – 7.87x104 0.261
24 1.01x104 0.035 2.55x104 0.095 4.75x104 0.158 3.25x104 0.108
28 – – – – 1.61x104 0.054 5.66x103 0.019
doi:10.1371/journal.pone.0138836.t002
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sample stocks were calculated and used to estimate the relative potency (pfu/ml) of the sample
by measuring the change in interpolated dilutions at IC50 between reference and sample stocks.
To estimate the agreement in the results for each sample between the new method and plaque
assay, calculated relative potency of a sample from HC-IA was compared to a titer value from
plaque assay (Fig 4). The results of correlation experiment showed that there is a strong agree-
ment between HC-IA and plaque assay (Pearson r-0.95, R2-0.9, Slope-0.83). These results dem-
onstrate that HC-IA measures vaccinia virus infectivity with the similar sensitivity as plaque
assay.
Fig 2. Variola virus infection in Vero E6 cells at different MOI at 24 hours post infection. Cell images were collected at 5X magnification with 9 fields per
well. Variola virus (Solaimen) was titrated at different MOI concentrations. Wells with uninfected control cells were included on each plate to be used for
gating purposes during image analysis. Cells were identified by nuclear staining (pseudo-colored blue) and virus presence was detected with indirect staining
(pseudo-colored green). Images show infected cells in one field per well at different MOI after 24 hours infection.
doi:10.1371/journal.pone.0138836.g002
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High Content Orthopoxvirus Neutralization Assay
Using vaccinia Wyeth virus as the target of neutralization, we prototyped development of the
high content neutralization assay (Fig 5). Based on the results from vaccinia virus infectivity
assay, we selected 17 hours incubation post infection with a viral MOI 0.25 that expected to
produce infection in approximately 90% of cells in the absence of any neutralizing serum. VIG
neutralized vaccinia virus infection at EC50 of 1.59 IU/mL, or at 1:2100 fold dilution of the
product. Similar neutralization experiments were conducted with monkeypox, cowpox, and
variola viruses, where cells were infected at MOI 0.25 and neutralized with titration of VIG, but
allowed to incubate for 24 hours post infection. Since infection dynamics experiment (Fig 1)
showed that monkeypox, cowpox and variola viruses grew at a slower rate than vaccinia virus,
we selected a longer incubation time, but kept the same MOI concentration. Cowpox and vari-
ola virus infections were 50% neutralized at VIG concentrations 0.9 IU/mL (1:3311 fold dilu-
tion) and 1.0 IU/mL (1:3295 fold dilution), respectively. Monkeypox virus infection was
neutralized at 0.3 IU/mL (1:12603 fold dilutions). The differences in VIG EC50 concentrations
are directly associated with observed infection dynamics for all tested viruses. According to the
results of monkeypox virus infection dynamics (Fig 1), infection at MOI 0.25 for 24 hours pro-
duces approximately 65% infection positive cells, whereas similar conditions for cowpox and
variola viruses correspond to approximately 80–85% infected cells, which require higher
amounts of VIG for virus neutralization.
Z-factor
To evaluate assay reproducibility we applied Z-factor statistical method (Fig 6). Vero cells were
either treated with vaccinia virus at MOI 0.250 (“Infected”), or a mixture of virus and pooled
human serum from previously immunized individuals at 1:100 dilution (“Neutralized”). Mean
and standard deviations of “Infected” and “Neutralized” wells were calculated and used to
determine Z-factor value. According to the results, the calculated Z-factor is 0.63, which falls
within the range for a robust and reproducible assay.
Fig 3. MicroChem treatment experiment. Treatment of cells with disinfectant after completion of staining procedure produced similar signal intensity as the
non-treated control. The Y-axis shows the percent of infected cells for each condition tested. The list of different conditions is shown on X-axis. MicroChem
treatment at the end of staining procedure produced comparable signal as control (No MicroChem).
doi:10.1371/journal.pone.0138836.g003
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Correlation between HC-OVNA and HCS-GFP
The mean EC50 values of serum titrations for three runs were collected for both assays and were
plotted against each other (Fig 7). Samples that did not neutralize viral infection (Category A
and C days 0, day 7) at 1:40 dilution were excluded from correlation analysis. The correlation
analysis between HCS-GFP and HC-OVNA was performed using ID50 values (HCS-GFP) and
Fig 4. Assay Concordance plot. Bivariate scatter correlation plot between vaccinia virus infectivity measured by high-content analysis based infectivity
assay (HC-IA) (Y-axis) and the plaque assay (X-axis) presented in log 10 scale. Potencies of thirteen stocks of vaccinia virus were measured in plaque assay
and HC-IA. Results were analyzed using GraphPad Prizm software showing significant correlation between image-based and standard plaque counting
assays (Pearson r—0.95, P value—0.0001, R2—0.9, slope 0.83). Dashed line represents the ideal linear curve with slope of 1, while solid line is an observed
concordance curve.
doi:10.1371/journal.pone.0138836.g004
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EC50 results (HC-OVNA) for 43 samples and appears to be significant with correlation coeffi-
cient = 0.9, and coefficient of determination = 0.8 (p value< 0.0001).
To further evaluate assay performance we used HC-OVNA derived EC50 neutralizing dilu-
tion values from correlation experiment and compared the changes in levels of serum neutral-
izing antibodies for different vaccinee categories. (Fig 8). The EC50 dilution results were
grouped by vaccination status (categories A, B, C, D) and then by serum collection days. The
EC50 results for each category were averaged and analyzed for days 0, 7, 21 and 6 months. For
the first time vaccinee (Category A) we were expecting to see a significant increase in neutraliz-
ing antibodies by day 21 and decrease in antibody levels by 6 months [12, 13]. Consistent with
our expectations the highest level of IgG response was observed on day 21, with EC50 at 1:960
serum dilutions (median 1241, range 348–1295). Neutralization responses from serum samples
collected on days 0 and 7 were rated as non-neutralizing with EC50 values below a 1:40 dilution,
since minimal to no neutralization activity was observed. By 6 months the amount of serum
Fig 5. Neutralization of viral infection with VIG. Vaccinia Immune Globulin was titrated in 3-fold serial dilutions starting from 1:50 dilution (66.67 IU/mL) and
was pre-incubated for 30 minutes at 37°C with test virus (cowpox, vaccinia or monkeypox viruses), or at 35.5°C for variola virus. Pre-incubated mixture was
transferred to Vero E6 cells and incubated for 17 hours (vaccinia virus), or 24 hours (cowpox, monkeypox and variola viruses).
doi:10.1371/journal.pone.0138836.g005
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neutralizing antibodies was reduced, resulting in EC50 dilutions at 1:280 dilution (median 263,
range 206–377).
Category “B” included serum samples from the same individuals as in Category “A” that
were re-vaccinated three years after first smallpox vaccination. We observed that the remaining
neutralizing antibodies present in serum on day 0 of re-vaccination were slightly lower com-
pared to the amount of neutralizing antibodies present in serum 6 months after primary vacci-
nation and almost 75% lower than on day 21 (category “A”). The increase in immune response
for category “B” was observed by day 7 and reached its peak on day 21 with EC50 dilution at
1027 (median 791, range 770–1521) and lowered almost 2-fold by 6 month (mean 495, median
323, range 241–922).
For Category “C” (re-vaccination after 30 or more years post primary vaccination) neutral-
izing response, from day 0 serum samples were rated as non-neutralizing with EC50 dilution
values below a 1:40. By day 7 a discernable neutralizing antibody titer (mean 112, median 97,
range 40–105) was measured, and reached its peak at day 21 (mean 290, median 191, range
113–596). By six months the amount of neutralizing antibodies has dropped slightly with
mean EC50 dilution at 270 (median 254, range 118–456).
The EC50 results of the immune response for individuals that were vaccinated multiple
times (category “D”) was relatively similar between all serum collection days, with a slight
increase in potency for day 21 serum samples. At day zero, the mean EC50 dilution was 160
(median 169, range 112–185) and slightly increased by day 21 (EC50 mean 215, median 204,
range 160–340), and stayed unchanged for six months (EC50 mean 210, median 218, range
110–277). It appears that with repeated vaccinations (category “D”) the EC50 dilution values
are lower than with initial vaccination or one-time three-year boost, and do not significantly
change depending on the day serum was collected.
Screening immune-response to immunization in prairie dogs
In this experiment we compared the results of the functional immune response measured by
HC-OVNA to the total amount of anti-Orthopoxvirus IgG antibodies measured by ELISA.
Serum samples from two prairie dogs intranasally challenged with monkeypox virus (strain
MPXV-USA-2003-044 at 5 x103 pfu) were tested in high-content Orthopoxvirus neutralization
assay using Wyeth vaccinia virus. Serum samples were collected on days 3, 6, 13, 20, 24, and 31
Fig 6. Assay reproducibility. Z-factor experiment was performed to evaluate assay reproducibility, where 20% of a plate had wells infected with vaccinia
virus at MOI 0.250, and the rest of the plate had wells that were infected (MOI 0.250) and neutralized with pooled human serum at 1:100 dilution Calculated Z-
factor value is 0.63 indicating that the developed assay is robust and reproducible.
doi:10.1371/journal.pone.0138836.g006
Orthopoxvirus Infectivity and Neutralization Assays
PLOS ONE | DOI:10.1371/journal.pone.0138836 October 1, 2015 13 / 20
post-challenge. No neutralization activity was observed on days 3 and 6 for PD 8141 (Fig 9A).
However, the first signs of virus neutralization were detected from serum collected on day 13,
followed by a gradual increase in virus inhibition from the samples collected on days 20, 24
and the day animal was euthanized (day 31). In PD 8124, neutralization of vaccinia virus infec-
tion was first detected from samples collected on day 20 and continuously increased until the
day of euthanasia (day 31) (Fig 9A). The results of the neutralization assay were compared
with previously performed ELISA data (Fig 9B) [11] and found two assays correlated. Similarly
Fig 7. Bivariate scatter correlation plot between two imaging assays.NewOrthopoxvirus neutralization assay (HC-OVNA), Y-axis, and GFP-expressing
vaccinia virus (HCS-GFP), X-axis, presented in log 10 scale. Correlation between two assays was evaluated using 49 human serum samples from smallpox
vaccine study (CDC IRB protocol 3349). Mean EC50 values from neutralization curves from HC-OVNA and HCS-GFP assays were plotted against each other
(log scale) and analyzed using GraphPad Prizm software, showing significant correlation between two assays (Pearson r—0.9, P value—0.0001, R2–0.8).
doi:10.1371/journal.pone.0138836.g007
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to HC-OVNA immune response to MPXV challenge was detected in ELISA on day 13 for PD
8141 and on day 20 for PD 8124 (day 17 serum samples were not available for HC-OVNA
experiments). While ELISA evaluates the level of specific anti-viral IgG antibodies that bind,
HC-OVNA is a functional assay that measures neutralizing activity of generated serum anti-
bodies against tested Orthopoxviruses, that could be used as a complementary assay in virus
challenge and vaccine studies.
Discussion
Our objective was to develop new high-content, high-throughput infectivity and neutralization
assays where Orthopoxvirus presence in a cell is fluorescently detected by a virus-specific anti-
body. We screened several commercially available anti-vaccinia polyclonal antibodies and
found that they cross-react with variola virus, cowpox virus and monkeypox virus due to high
genetic similarities found between members of the Orthopoxvirus genus. That allowed us to
develop generic Orthopoxvirus neutralization and infectivity assays. However, the availability
Fig 8. Average immune response for different vaccinee categories. Neutralization responses for each vaccinee category were grouped according to
blood draw days. Calculated average and standard deviation values were based on the results from several vaccinee per each category.
doi:10.1371/journal.pone.0138836.g008
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Fig 9. Screening of immune response to monkeypox virus challenge in prairie dogs. A. Serum samples from the monkeypox virus challenge study in
prairie dogs were tested in high-content Orthopoxvirus neutralization assay at four-fold serial dilutions, starting from 1:40 dilution.B. Evaluation of antibody
production in prairie dogs post monkeypox virus challenge using ELISA.
doi:10.1371/journal.pone.0138836.g009
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of Orthopoxvirus species-specific antibodies would allow adapting the infectivity assay into a
specific diagnostic test.
In HCA assays, an infectious virus is detected per cell and its amount is reported as fluores-
cent intensity directly associated with antibody-stained virus. The advantage of HC-IA and
HC-OVNA assays is the ability to detect the presence of an infectious virus significantly earlier
than in plaque-based infectivity and neutralization assays. In imaging assays, vaccinia virus
was detected 17 hours post infection, while in the plaque-based assay viral titers were measured
after 48 hours of incubation.
Another advantage of these methods over plaque-based assays is the higher statistical signif-
icance of the collected results. During acquisition we gather data at 5X magnification, covering
approximately 65% of the well, which corresponds to nearly 10,000 cells for each titration
point in a series of eleven serial dilutions. Viral presence was detected per cell, at the early
stages of foci formation. Collected results from a dilution series contribute to the calculations
of IC50 and EC50 for infectivity and neutralization assays, respectively. At the same time, in pla-
que-based assays, viral titers were calculated based on the number of plaques found in the well
corresponding to one dilution point. In the infectivity plaque assay viral dilutions that pro-
duced too many, or too few, to count plaques were excluded from the measurements. In addi-
tion to that, the working volumes of viral stocks and serum samples are significantly lower,
than in plaque-based assays. In imaging assays we used 5 times less virus material than in pla-
que assay; and for virus neutralization experiments 5μL of serum was enough to start a dilution
series. These low volume requirements not only alleviate the need to produce more viral stocks,
but are also very important when serum sample quantities are small, especially when they
come from miniature animals.
In the course of assay development we observed that four tested Orthopoxviruses have dif-
ferent infection dynamics when used at the same MOI concentrations. Consistent with prior
observations, vaccinia virus grows the fastest among tested Orthopoxviruses and requires 17
hours infection to reach similar IC50 results as cowpox, variola, and monkeypox viruses with
longer incubation times. At 24 hours post infection the IC50 values for vaccinia virus were
almost five times lower than for monkeypox virus, making them the fastest and the slowest
growing viruses, respectively. The developed infectivity assay was compared to plaque assay for
estimation of viral stock potency. In our current version of the plaque assay, vaccinia virus
grew in a medium that does not restrict viral spread, therefore, making incubation conditions
for two assays somewhat similar. Comparison of viral potencies measured by both assays
showed that two methods have a good agreement in the estimation of viral stock concentra-
tions. However, HC-IA is a high-throughput test, which is less labor-intensive, and offers
shorter turn-around time. Since commercially available vaccinia virus detection antibodies
cross-react with other Orthopoxvirus species, the developed infectivity assay could be applied
to measure viral stock concentrations of variola, cowpox, and monkeypox viruses, by adjusting
incubation times that reflect each species growth dynamics.
Based on growth dynamics of vaccinia virus, for the development of neutralization assay, we
decided to use MOI 0.25, which yields approximately 90% of cells infected at 17hpi. Applying
the selected conditions for vaccinia virus infection neutralization experiment with titration of
VIG resulted in a curve with more than 2-logs in dynamic range, which was used to estimate
the EC50. We observed somewhat similar results when vaccinia virus neutralization conditions
were applied to cowpox and variola viruses, but with longer incubation time (24 hours incuba-
tion). The EC50 values for VIG are very similar between the three viruses. However, selected
infectivity conditions for monkeypox virus (MOI 0.25 for 24 hours) produced EC50 values
lower than we observed for other tested viruses, which is expected, since above conditions
should produce only 65% of infected cells according to growth dynamics experiments. We did
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not further optimize neutralization conditions for monkeypox virus infection, since this was
not an objective of this study, but we believe that MOI 0.125 for 28 hours incubation would be
optimal for virus neutralization with titration of VIG.
As a part of assay validation the comparison of the results from HC-OVNA with the results
from HCS-GFP neutralization assay showed that two methods are very comparable, with
high correlation coefficient value. To validate this assay further we evaluated the results of
HC-OVNA for each vaccinee category and compared with available reports on changes in
immune response after smallpox vaccination. Consistent with our earlier observations [13] for
first time vaccinee the significant increase in immune response was observed by day 21. At six
months the amount of neutralizing antibodies was almost 3 times lower than on day 21 post
primary vaccination. It was previously reported that levels of neutralizing antibodies in pri-
mary vaccinee one year after vaccination were more than four-fold lower than on day 28 post-
vaccination [12]. We saw that the remaining neutralizing antibodies present in serum on day 0
of re-vaccination (Category “B”–three year boost after primary vaccination) were slightly lower
compared to the amount of neutralizing antibodies present in serum 6 months after primary
vaccination and almost 75% lower than on day 21 post primary vaccination. The increase in
immune response for Category “B” was detected by day 7 and continue to increase with highest
reported value on day 21 following by almost 2-fold decrease by 6 month.
For Category “C” (re-vaccination after 30 or more years post primary vaccination) neutral-
izing response, from day 0 serum samples were rated as non-neutralizing with EC50 dilution
values below a 1:40. However, similar to category “B” the immune response start to increase by
day 7 (mean 112, median 97, range 40–105) and reached its peak at day 21 (mean 290, median
191, range 113–596). Observed increase in neutralizing antibodies by day 7 could be associated
with the presence of long-lived memory B cells. It was reported that long-lived memory B cells
can produce rapid increase in antibody secretion upon re-vaccination after 30 or more years
post initial vaccination [14]. As we saw with categories “A” and “B” the amount of neutralizing
antibodies was slightly lower at 6 months compared to day 21 post vaccination.
It appears that with repeated vaccinations (category “D”) the EC50 dilution values are lower
than with primary vaccination or first time three-year boost, and do not significantly change
depending on the day serum was collected. Earlier reports showed that presence of circulating
neutralizing antibodies in the serum of multiple time vaccinee, in addition to strong a cellular
immune response triggered by re-vaccination, leads to a fast and complete destruction of the
virus at the initial stages of immune response [15, 16].
In addition to experiments with human serum, we conducted a small-scale set of tests using
prairie dog serum samples from monkeypox virus challenge study [11] and compared neutrali-
zation results with previously performed ELISA data. Although two assays measure different
antibody functions (neutralization vs. binding), we found a good correlation between both
assays. While the results of ELISA indicate an increase in antibody presence, HC-OVNA fol-
lows the same response pattern showing neutralizing activity of tested serum, making two
assays complimentary to each other.
Conclusion
In this paper we described the development of new high content analysis infectivity and neu-
tralization assays that are compatible with multiple species of Orthopoxviruses, and were tested
with four species (vaccinia Wyeth, variola Solaimen, monkeypox MPXV-USA-2003-044, and
cowpox Brighton). Both assays are based on viral immunodetection with commercially avail-
able anti-vaccinia polyclonal antibodies. Due to a high degree of genetic similarity between
Orthopoxviruses, our newly-developed assays could be applied to different members of
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Orthopoxvirus genus utilizing commercially available polyclonal antibodies. These assays are
particularly valuable for analysis of viruses which cannot be genetically modified, like variola
virus, and may replace the traditional plaque and plaque reduction neutralization test (PRNT)
assays. The high throughput methods possess several advantages over the traditional PRNTs:
require very small amounts of test material, less labor intensive, require shorter incubation
times than traditional methods. Collected images are stored on a secure server and could be re-
analyzed for additional parameters associated with infection, like morphological changes in
cells, variations in nucleus size, texture analysis and others. In addition, both methods could be
combined with cytotoxicity and apoptosis assays to measure cellular response to a new drug
and viral infection in-vitro, instead of, or before expensive animal model studies.
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